Please login to the form below

Not currently logged in
Email:
Password:

Novartis Pharma

This page shows the latest Novartis Pharma news and features for those working in and with pharma, biotech and healthcare.

Poseida gets Novartis backing for myleoma CAR-T challenger

Poseida gets Novartis backing for myleoma CAR-T challenger

Novartis. The San Diego-based start-up company has developed a range of non-viral gene engineering technologies to create a pipeline of autologous CAR-T therapies, with its lead candidate ... Eric Ostertag. “We welcome the support and investment from

Latest news

  • Novartis makes case for gene therapy Zolgensma in SMA Novartis makes case for gene therapy Zolgensma in SMA

    disease,” said Olga Santiago, MD, Chief Medical Officer, AveXis, a subsidiary of Novartis. ... While Zolgensma’s price won’t be revealed until it’s approved for market, Novartis confirmed it is exploring instalment-based payment models to

  • NICE says no to Novartis’ Kisqali combo in breast cancer NICE says no to Novartis’ Kisqali combo in breast cancer

    Double blow after Lilly rival recommended. Novartis’ hopes of a boost for under-performing breast cancer drug Kisqali have been hit by a negative verdict from NICE. ... Novartis has struggled to gain traction in the CDK 4/6 inhibitor category, with

  • Novartis and Amgen come to blows over migraine partnership Novartis and Amgen come to blows over migraine partnership

    The immaterial contract manufacturing services being provided by an entity that is part of a separate division from Novartis Pharma are not ‘distracting’ Novartis Pharma from developing and commercializing Aimovig,” it ... That profile means that

  • Novartis claims first place for psoriasis drug Cosentyx in China Novartis claims first place for psoriasis drug Cosentyx in China

    safety in more than 200, 000 patients worldwide and can deliver what doctors and patients are looking for,” said Paul Hudson, chief executive of Novartis' pharma division. ... China is a growth target for Novartis, although the company has admitted it

  • Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

    Acquires its portfolio of NLRP3 targeting drugs. Novartis has snapped up an emerging company working on drugs for inflammation, paying $310m upfront for Boston-based IFM Tre in a deal valued ... Novartis is buying into that hope by acquiring IFM Tre’s

More from news
Approximately 6 fully matching, plus 475 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    We are in an era of great change and treatment advances,” says Gitte Aabo, CEO and President of Leo Pharma. ... It makes it very attractive not only for Leo but for big pharma companies such as Novartis and Celgene that are very active in this area.

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    they do badly,” added Mr Moran, who joined Novartis from McKinsey &Company as a strategic assistant to the CEO in January 2015. ... A one-off treatment, it comes with the hefty $475, 000 price tag - and a red rag to anti-pharma factions - but put

  • Bridging pharma’s digital gap Bridging pharma’s digital gap

    But in true pharma fashion, that leap was not without its side effects. ... What Novartis and all the other pharma companies are trying to do is distil the myriad content that they have available at their fingertips and transform it into something useful,

  • Are we #winning? Are we #winning?

    We’ve seen multiple online ‘TV’ channels launch from medical societies and congress; some (eg ASCO) have commoditised their assets, and - for example, with Novartis’ VivindaTV.com - pharma is now competing ... As this transformation continues at

  • Deal Watch December 2016 Deal Watch December 2016

    295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m.

More from intelligence
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

  • Marketing strategy in complex environments

    Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines. ... The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment.

  • Experienced Healthcare Marketer Gareth Thurston, joins Cello Health Consulting

    Gareth has over 20 years’ experience in senior roles in a number of pharma companies, most recently at Novartis, where he spent seven years in various roles, including Brand Lead Opthalmology, ... biggest pharma companies.” Gareth will be based at

  • Cogora

    Circassia. GE Healthcare. GlaxoSmithKline. Grunenthal. Indivior. Mallinckrodt. Mylan. Nestle. Novartis. Novo Nordisk. ... Nutricia. Orion Pharma. Orphan Europe. Pfizer. Portola. Prostate Cancer UK. Primary Care Respiratory Society.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics